Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sales Q4 2012: 182 K
Sales Q4 2011: 440 K
Please bear in mind that prices (endprice consumer and thus wholesale prices ex factory) have been substantially reduced between 2011 and 2012.
Inventory may have been valued at historical earlier (higher) prices. Eventually they would have to partially write off this overvaluation.
Dilution, once again
40 mill shares @0.0016 = 64.000 US$ for the company
Sad story, they can't get it right
For some years, turnover in Q3 has always been exceptionally low.
Expect "normal" numbers, or if being optimistic "great" numbers in Q4. This forthcoming number should give us a real indication as to whether the business is finally moving forward (Spanish distribution rumoured to be in place etc...
Numbers traditionally to be published around Feb. 15th
How stupid can stupid management be?
(It's an explanation for the abysmally low sales figures as well)
At amazon.co.uk they managed to list under...
Health & Beauty › Health Care › Alternative Therapy › Magnetic Therapy (that's right, next to the gizmo's such as the magnetic healing armbands)
...whereas most if not all pain relief is found, and anyone with a single brain cell should have it categorised, under:
Health & Beauty › Health Care › Medication › Pain Relief › Topical Relief
If it's negligence, it borders on criminal negligence.
If its stupidness, management should retire at once for being the most retarded .... (please fill in) we're ever about to see
Having been in DNDN at time of approval, I don't feel I'm being unrealistic. So many more indications (open goals) available for Visticrine....
9 to 10$ easily which equates to a market cap of 200 millions.
Indications, conditions... for which this drug is suitable treatment are very expandable in near future
I see my message has been deleted, but yes, some people are indeed and completely clueless as to the way to grow or run a profitable business (BTW yes, I've been in start-ups and i repeat: succesfully, but coming up with no results after two years would have gotten me fired for sure).
What is your track record for starting businesses ? And what is AW's track record ?
So they need the dilution, to pay wages.
Fine, if the personnel (or the CEO) achieved anything.
Name one achievement for the last two years:
Canada: NO
FDA Clearance: NO
International sales: NO
In my book if personnel was unproductive and didn't meet there goals, they were fired.
Don't tell me they couldn't have waited a couple of days in order to have the golden cross confirmed. That way BIEL could have raised a lot more money from the same dilution. Dilution at this very moment is so counterproductive to each and everyone party involved, that it becomes unforgivable thereby showing a total lack of respect for shareholders and their justified interests.
Bye bye golden cross as our most brilliant CEO (NOOOOTTTT) is shooting in his own foot, and everybody else's, by diluting again.
Stupidity knows no boundaries with this ... (I don't know what I should call him, but if I knew I would be violating the board's rules for sure)
Regarding this meeting, I'm somewhat impressed (and this is a first for me) by the qualifications of the people that attended the meeting on BIEL's behalf. Real professionals for once, which hasn't always been the case.
Nail on the head!
You can deduct the dates as somewhere between May and August 2011
from their Pr release 23/5
The patent application relates to the use of radiofrequency induced, safe, inexpensive, convenient, 7-day or longer continuous deep heat treatments. The new thermal mechanism of action is in addition to the electrical field therapy, to provide a highly effective dual mechanism of action.
(...)
this additional product feature, when combined with our current patented pulsed treatment, will provide a compelling competitive advantage over drugs and hot and cold therapies.
and from the PR release of August 8th
(BIEL) has filed a response to the FDA concerns on the mechanism of action for the Company's Allayâ„¢, Menstrual Pain Therapy product. This response is predicated on additional physiological research, independent studies, and confirming bench testing to verify the working basis for the clinical results produced by its therapy. The research has established a unique patentable mechanism of operation and justification for moving the device into the FDA's lower safety Class II category. Additionally, the defined safety profile of the mechanism of operation demonstrates less risk than the FDA's approved Class I, over-the-counter heat products.
(...)
The energy emitted by the Allay device was previously thought to act as only an undefined non-thermal mechanism. We have provided the FDA with extensive performance data that establishes the physics and clinical efficacy of our exceptional therapy. The Allay device offers a simple way of providing dual electrical and continuous low-level, safe, deep heat therapy.
(...)
Last week we announced that we are expecting a near-term decision from FDA relative to our RecoveryRxâ„¢ surgical recovery product. Our FDA reclassification filing for our Allay Menstrual Pain Therapy product is a separate issue and thus we are now waiting for a second separate decision. We have approached both responses to FDA based on hard scientific facts and we believe we have supplied the examiners with a strong body of evidence in answering their questions. We are eagerly awaiting near term FDA's responses relative to both of these profound healing and pain relieving therapeutic agents."
As far as I can understand, they tacked a heating device onto the PEMF device and (re-?)submitted it as a Class II heating device.
It's like putting an A/C in a car and then claiming it is a cooling device (thereby insanely hoping car safety tests can be avoided or something along those lines).
If that's the case
1/ the FDA is right in its refusal
2/ BIEL's submittal process is completely botched, takes on all wrong directions, has cost/is costing a lot of money and does not take us anywhere near approval. Same for the steps undertaken with the senator and the IG.
3/ What in the hell were they thinking: did they really think they could outsmart the FDA ?
4/ Being overly agressive with the FDA, while at the same time forwarding a botched submission for approval is not going to help their standing with the FDA at all.
Déjà vu: BIEL once again messes up big time.
Also you can wonder how long ago they knew about this letter. And if they were diluting in the mean time.
Hope they sell the patents soon. Anything better than the present management that's only costing money, diligently working on ruining the chances of eventual success of the product.
Looks to me like dilution by AW "don't know to get anything right and never ever delivering on promises"
None the wiser, uninformative answers
Hereby copy of my mail. Answers by Paul Knopick between brackets
As a BIEL's shareholder, I've been informed several times over the last year about an imminent distribution launch in Canada.
However, I am missing hard facts about the eventual progress of this endeavour.
Therefor, I would like you to provide me, if possible at all, with some hard factual information regarding this launch:
1/ -Is there firm commitment by Greenwood as to numbers and/or deadlines ? YES,YES/ NO, NO
(Don't understand the question. We would not discuss numbers and deadlines anyway.)
2/ -Are there commitments by Greenwood or distributors as to marketing efforts and budgets ? YES/NO
(Again, when we have something to announce, we will announce it for all shareholders. I don't believe in doing this in a piecemeal basis.)
3/ -Has a marketing plan been drawn up, either below the line (in store presence such as displays and the like, PR... ) or above the line (advertisements be it in periodicals, magazines, radio, TV...) (YES/NO)
(Internal marketing issues are not something we would discuss.)
4/ -Does BIEL have all necessary funding in place for realising this launch (YES/NO)
5/ -Does a business plan/forecast exist matching expenditures and revenues forecasts of the entire operation (YES/NO)
6/ -Are there to date any signed agreements with supermarkets/retail chains/drug stores in Canada (YES/NO)
(4-5 and 6: Again, when we have something to announce, we will announce it for all investors. Thank you for your continued interest.) Paul Knopick for BIEL
Mail has been sent and hard factual information asked
Do you expect a satisfactory answer ???
What do you want. Todays news is a non-event.
Didn't you notice that in BIEL's communication regarding the infamous Canada's launch is fading mysteriously into the background...?
This launch was announced for early fall last year, then late fall, then before the end of the year for sure, sorry mistake let's say early in the new year but OUCHHH some obscure rearranging of shelf space had to take place (or NOT Apparently)...
And here we are almost summer a year later and I now doubt we are going to see some firm action before the summer recess.
This takes us into next fall where the washing cycle can begin again (rinse, launch early fall, late fall, tumble, before the end of the year, dry.... blah blah blah)
Point is, only hard facts about the much touted Canada launch can take us substantially higher (and they have full control over/responsibility regarding this launch as opposed to the FDA clearance where they are dependant on a third party).
If someone would be so good as to give me the contact details of the PR agency, I would be glad to send them an email regarding factual information re the Canada launch.
Ah, the disruptive price strategy of Biel: another piece of lunacy.
You see, the great leader of BIEL (NOT) has not a chip, but a parrot on his shoulder.
First this parrot was shouting SOON (FDA clearance, Canada launch), but I've become very wary and unsure of the meaning SOON when used in the same sentence as the word BIEL.
Now the parrot is shouting "disruptive pricing strategy"
As "interesting" as it may sound, this is utter nonsense.
- If you set your price point too low, psychologically people tend to suspect your product is worthless, flawed, a gizmo... in each and every case losing lots of credibility
- There is ABSOLUTELY NO need to lower the price unless the competitor does so. Why on earth would you go for totally unnecessary price cuts if you could have used the foregone margin for extra marketing (= better acceptance) , extra profit, extra return for the shareholders.
Please allow me to seriously doubt the intellectual capacities and the business acumen of the parrot (please note here: I abide the rule of no personal attasks on people)
Just a hunch, but a couple of days ago, Color of Money made a short reappearance of this board.
This person acts as a spokeperson for Biel,in that he's allways on the phone with the infamous AW and apparently has a privileged line with the great leader (NOT) of Biel.
Now that AW no longer shoots his mouth off, we have Colour of Moneys as an alternative channel to hear the latest very unofficial news about BIEL, including forward looking statements, speculations and the like.
In his latest statement a few days ago C of M reiterated that FDA clearance was now very soon. Just like AW's statement last august...
Now who's the pumper, and what is the definition of soon ?
Big buys ?
I see some small sells bringing it down
Going from 0.0021 to 0.0020 on a a sale of 1700 shares which equals... 3 dollars ?
Given the professional references of Greenwood,the experience of its employees, seeing the companies they've worked for, I very much doubt Greenwood is the issue here (as has been the discussion today).
Given my understanding of BIELS activities over the last 3 years, I am more inclined to think about a mishap on BIELS' side as the explanation of the lack of progress in Canada. Mishap: remember the completely unauthorised amateuristic (what were you thinking, were you thinking at all, AW?)distribution of Actipatches last fall which was subsequently and completely halted by the FDA-letter. To me this was a grave professional mistake, a waste of money, credibility, trustworthiness etc..., etc...
Yes, I'm guessing they are pulling another "run it completely into the ground-stunt". Dunno wht they are doing, but I've come to fear the worst.
Your #7 is not correct.
Dilution over the last months netted them around 1,5 million dollar.
However, apart from the infamous trips to a.o. Dubai, there has been no indication on the ways they are going to spend/invest the money nor do we know whether they're going to spend it wisely (apart from salaries of 8 people (last I've heard) who in return have no accomplishments to show for whatsoever over the last 3 year - and this IMHO is money unwisely spent).
I share your confusion.
Few weeks ago, goals of 2 to 5$ we're set for PPS after the advisory committee. Instead, this goes from 90 cents to a spike of 1.10 back to the mid-70's. I'm baffled, I see no reason at all for this to tank on good news.
It cannot be Deerfield since a) they only sell around a dollar and b) yesterday's volume laregely surpassed the 1,3 million shares they intend to sell.
Anyone can offer a logical explanation ?
AF's twitter is biased to say the very least.
Marqibo is administered to heavily pretreated patients, i.e. patients with no more options/medicines left. In the natural course of things, they are, unfortunately, dying. Marqibo prolongs life but not for all patients, and therefor it cannot will not prevent all deaths.
It is sad that someone must misrepresent these facts, abusing the ill fate of dying people.
It makes you also wonder what the effect of Marqibo would be if applied at an earlier stage of the concerned diseases.
a) nothing new in the update. Just a rehash of the previous update.
b) no mention at all of the status of important events such as Canada Launch, FDA approval (hey, they've could have called FDA to know how things are going along, but NO this sadly has not come to their ape-like brains)
c) no follow-up either on recently announced news (the CEUTA-conference ! the Dubai-conference !) which they were so THRILLED about. How it was going to change the world, or something along those lines but looking like a dead-end (again!)
d) still no numbers on Q4 (should have been published on Feb. 15th,
and we're now March 15th)
e) This is an update by morons intended for morons (which i'm not taking or accepting, It's more linke insulting to me but that's just a personal feeling, what's more important is the consequence under f))
f) The market is not buying it (the market is always right) hence we're now at 0.0020 and 0.0001 is on the horizon.
I wish they would stop the bullshit, for once
From the answer you received, it is clear that the individual stores decide for themselves what they put on the shelf or not.
Yet, at about the same time in January, the reason invoked for (another) delay in Canada was the so-called allocation of shelf space (as a companywide decision for the major drug retailers involved)
Now which one of the above statements is true ?
And who's lying ?
a) Shoppers Drug Mart
b) Greenwood Group
c) the clown who thinks he's a CEO
With thanks to fbsf32 for the much appreciated efforts
They've already increased the A/S
What's more, I'm under the impression that they are diluting again these last two days.
Suspicious as I've become of management, I wonder if there is a relation between the PR earlier this week and the dilution.
My conspiracy theory in this matter is as follows: first you launch the PR to boost PPS, in the subesequent days you try to capitalize on the rising PPS to get more bucks out of dilution.
Fartetched as this conspiracy theory might be (and they're always farfetched), it is a sad illustration of the levels that my mistrust in this non-management have reached lately.
Let me remind you of the Canada launch again: late summer, early autumn, late autumn, definitely before the end of the year, first thing in the new year, oops forgot to clear the shelf space, we're clearing the shelf space maybe, not a single word about Canada in the latest PR although everyone agrees that's one of two binary events, anyway count on a Canada launch SOON, IN THE COMING NEXT WEEKS (as were the words of clown AW to describe the FDA approval way back in August).
So yes, some feelings of complete disbelief are creeping into my mind, and sadly, not a single communication from BIEL, is reassuring.
Big deal: the umptied deal with a new distributor (yawn, have heard this so many times before)
I would be much more interested in Q4 financials. Normally they were due Feb. 15th, but nothing has come our way.
This news we're waiting for and which really matters (and factual news at that) is delayed whereas non-events (new distributors) are plentiful or other announcements (such as the imminent FDA-approval in august) are released way too soon.
Given this poor PR-policy which lacks all credibility by now, it's understandable that PPS doesn't move on this "news"
Stupid question: the original approval for RX Recovery for Post Eye surgery care dates from around 2002 or 2003
Why did they wait till 2009 to start thinking (only thinking and talking about it, not really taking action) about approvals for other (commercially much more significant and viable) uses ?
Were they sleeping ? Did they have sand in their brain ?
IMHO opinion it also says a lot about prioritizing, sense of focus or plain professionalism at BIEL, if it takes them about two years to get together their application.
I also remember the infamous Joe Noel being involved in the application (and for God's sake even conducting a study, the scientific merits of which you can imagine).
You're someone who knows, predicting accurately
Any more comments on the actual situation would be greatly appreciated.
I'll bet it worked wonders for your peace of mind.
I'm stuck with the doomed (the pissed-off feeling)
Let's hope and prey for FDA approval or a take-over.
Anything to get rid of this clown who's adding insult to injury.
Exactly my frustrated feeling
Management does everything wrong...
...and there is no end to it.
This FDA problem illustrates it once again.
They knowingly (or, which would even be worse, unknowingly) violated FDA rules ("The Act") and it blows up in their face.
False unproven therapeutical claims, omitting clauses as to the need for prescription, .. it goes on and on.
They were amply forewarned given a.o. the various posts on this board.
Does it matter that they've lost all credibility? Of course, it's another blow to PPS, and it will turn out to be a serious one.
Earlier suggestions for BIEL as to sit completely still and do not waste money until FDA approval make more and more sense: that way they cannot commit the monstruous mistakes of this kind. Yet the clown who thinks he's some CEO of this firm still doesn't realise the time he should step down is long overdue.
As I've said before my nephew of 6 years (but he's now about seven) would do a better job at running this company.
Kudos to Stockdarockk for bringing this to the board.
A few things about this clown AW which are definitely cons:
Promises, promises, and just promises which are always broken:
Imminent launches in Canada or the UK,as far back as 2009, none of the them have materialised yet.
Overly positive statements such as the August 2011 statement "FDA approval within the next weeks", once again never materialised.
Repeating the same mistakes again and again: announcing an endless list of distribution deals all over the world (India, Inner-Mongolia, Outer-Mongolia, you name them...), announcing each time that this distribution deal is going to move forward BIEL, whereas the quarterly statements sadly show none of these deals ever brought in significant money. After 3 years of the same mistake, you would have hoped that someone finally would have seen that this distribution model DOES NOT WORK. But hell no, this clown goes forward , and we are now in the 4th consecutive year of the same money-losing strategy (see also the next point, about Dubai for instance)
Complete lack of focus: as I calculate it, dilution of the past few months could have raised (the greater part of) the money necessary for the Canada launch. Unfortunately, at the same time this money is available, I start seeing them attending conferences again (oddly enough, all in warm places such as Dubai). Thus, they divert the money necessary from the Canada launch, which is directly endangering the success of the Canada launch.
Some posters earlier suggested that BIEL halted all operations and focused all their efforts solely on the FDA approval. Given the complete waste of money resulting from their existing operations (as elaborated above), I tend to agree with them.
If Biel was to enter the competition for the worst run company, they would stand a very good chance.
No paint, establishing a base above 0.0100, and more likeley moving between 0.110 and 0.0120 next week. Some sort of consolidation if you like
And, as an afterthought:
Where does this money come from ? Dilution, I'm sure. So the trip to Dubai is at a direct detriment of shareholders, i.e. a waste of my and your money.
No reason to focus on unnecessary expenses of 1O's of thousand of dollars ?
Are you joking ?
Isn't it the point of more members of this board that money has been, and is still being, allocated very unwisely ?
Isn'it the point that they lack, a.o., focus and strategy for a clear path to success ?
Technically, the chart is indeed ready to run.
As is the spread.
Only volume is missing.
I'd like to add this about cutting the expenses.
Recently they attended the Dubai Conference.
While it is nice to escape from winter weather and have a break in the sun, cost vs revenue of this trip do not add up at all.
Cost of flights, hotel, conference participation...in the tens of thousands at least.
Revenues: no PR's at all as to a possible dealership contracts (and even if they signed a contract, never ever was there a positive financial result of the dozens of the so-called distribution agreements they've alledgedly signed in the past all over the world).
So Kidnova, you're right, shotgun spending, basking in the Dubai sun even, but never some tangible results.
Kidnova is right (on more counts than this one)
It was in their financial statements.
And as far as clinical trials go: the infamous Joe Noel ran a couple for them in the beginning. Tells a lot about the professionalism of clown AW